Why CRISPR Therapeutics Soared 13.8% Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) jumped by 13.8% on Monday, after the clinical-stage biotech company announced some exciting news regarding one of its leading pipeline candidate, CTX001.
CTX001 is an investigational treatment for Sickle Cell Disease (SCD) and transfusion-dependent beta-thalassemia (TDT), both of which are rare blood disorders. Today, CRISPR Therapeutics reported that the U.S. Food and Drug Administration (FDA) granted CTX001 the Regenerative Medicine Advanced Therapy (RMAT) designation. This designation is reserved for drugs or treatments that meet three criteria.
Image Source: Getty Images.
Source Fool.com
